SCHEMBL1903574

SCHEMBL1903574

O=C(Nc1ccccc1)c1cc[c]cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
TDP1 Q9NUW8 2/20 0.57
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 5/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 2/20 0.49
TP53 P04637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GAA P10253 1/20 0.49
METAP2 P50579 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX12 P18054 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16095595 0.87 NPC1 (0.58) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL2514344 0.79 MEN1 (0.65) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL4363732 0.79 MEN1 (0.89) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL744223 0.76 GAA (0.56) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL232644 0.75 ALB (0.41) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL14825062 0.73 NPC1 (1.00) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL17115776 0.73 NPC1 (1.00) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL6544935 0.73 GPR27 (0.72) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL1206852 0.73 KMT2A (0.38) NPC1RAB9AKMT2ALMNASMN1; SMN2
SCHEMBL437231 0.72 ALDH1A1 (0.87) NPC1RAB9AMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 NPC1 1378/4885RAB9A 2116/4885MEN1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.